{"nctId":"NCT03673943","briefTitle":"Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE","startDateStruct":{"date":"2018-08-23","type":"ACTUAL"},"conditions":["Neuroendocrine Tumors"],"count":63,"armGroups":[{"label":"PET/CT imaging with 64Cu-DOTATATE","type":"EXPERIMENTAL","interventionNames":["Drug: 64Cu-DOTATATE"]}],"interventions":[{"name":"64Cu-DOTATATE","otherNames":["NETMEDIX"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Confirmed or suspicion of NET based on histology/ biopsy report.\n* Confirmed or suspicion of NET based on conventional imaging scans of affected area such as MRI and/or contrast enhanced CT and/or an FDG PET\n* CT scan and/or NaF PET-CT scan and/or OctreoScan速 performed within 8 weeks prior to study date.\n\nExclusion Criteria:\n\n* Pregnant, planning to be pregnant within the next two weeks\n* Inability to provide written consent.\n* Therapeutic use of any somatostatin analogue, including Sandostatin速 long-acting and Lanreotide (within 28 days) and Sandostatin速 (within 2 days) prior to study imaging. If a subject is on Sandostatin速 long-acting or Lanreotide, a wash-out period of 28 days is required before the injection of the study drug.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Sensitivity of 64Cu-DOTATATE PET-CT Imaging for Detection of Somatostatin Receptor Positive SSTR (+) Tumor","description":"The number of patients with NETs disease that was confirmed by SSTR(+) imaging using 64Cu-DOTATATE PET/CT and In111-Octreoscan (considered as the standard of truth imaging) A total of 63 subjects have been enrolled in the studies; among them 42 patients with known or suspected NET based on histology, or conventional imaging, or clinical evaluations and 21 healthy volunteers.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]}]},{"type":"PRIMARY","title":"Specificity of 64Cu- DOTATATE PET/CT Imaging for Detection of Neuroendocrine Tumor","description":"The number of subjects who have no SSTR (+) NETs as determined by 64Cu-DOTATATE PET/CT as well using the standard of truth imaging (In111-Octrescan SPECT/CT).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Detection of Localized or Metastatic SSTR Positive NETs Lesions Using Both 64Cu-DOTATATE PET/CT and Standard of Truth Imaging","description":"The number of patients with localized NETs or metastatic SSTR(+) neuroendocrine tumors that were detected by both 64Cu-DOTATATE and SOT","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"28","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":63},"commonTop":["vomiting (both grade 1)","nausea (grade 1)","headache (grade 1)","syncope (grade 2)","melanoderma (grade 1)"]}}}